Welcome to Mx’s (to be pronounced as emukk’s) Homepage
July 19th, 2024 is the fourth Anniversary of this homepage. Mx will be holding a half price sale on GSR2300 as the 4th anivversry event (First come first served, only 1 unit available). Current main issues on Mx homepage are as follows. Basically, Mx is a research and development type business entity.
- General biological phenomena related to Glycans and Lectins and those application to real life
- Realization of sustainable and regenerative agriculture and food safety
- Evanescent-field fluorescence excitation Glycan Profiler (GlycoStation®)
- Biosensors for detecting microbes (Optic Biome Sensor)
- Easy to use Statistical Analysis & Deep Learning Software (GlycoStation®SA/DL Easy)
- R&D consumables (Culture media for MSC, Special Culture media, Lectin, etc.)
News (the 4th anniversary event: Half price sale)
Mx will be holding a half price sale on GSR2300 as the 4th anniversary event. First come first served, limited to only 1 unit. Please contact us for special pricing. (May 3rd, 2024)
News (Carbohydrates related International Conferences)
Carbohydrates related International Conferences which will be held in overseas in 2024-2025 was summarized. (May 7th, 2024)
News(Updated Information about GlycoStation Related Products)
The most recent Information about GlycoStation related products (GSR22300, GSL-2200, and IgG1-mAb-LecChip) was uploaded for your information. Since some Video were embeded in this document, PowerPoint was used instead of pdf. (Feb. 1st, 2024)
News(A tailored Lectin Microarray for therapeutic mAbs)
FDA has published a paper on lectin microarrays for simple and rapid therapeutic mAbs. This result was also a joint study between FDA and GlycoTechnica. In this paper, Glycan Profiler GSR2300 and 14-well lectin microarrays using 9 kinds of carefully selected lectins were used. (Jan. 26th, 2024)
News(New Year’s Greetings)
A Happy New Year.
Thank you very much for your help and support for our company during the past year. We look forward to continuing work with you in 2024.
We could successfully complete our first fiscal year, and achieved a surplus with debt-free management.